G. Li

发表

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

S. Yamazaki, P. Vicini, J. Lucas, 2016, Clinical Cancer Research.

HSP60 in cancer: a promising biomarker for diagnosis and a potentially useful target for treatment

Xing Tang, Qing Yu, B. Sun, 2021, Journal of drug targeting.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2015, Oncotarget.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Woo, Joon, Zachary, 2015, Oncotarget.

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

G. Brodeur, V. Kolla, P. Guan, 2016, Cancer letters.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.

Judy Lucas, J. Lucas, E. Rosfjord, 2014, Biochemical pharmacology.

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

M. Ladanyi, A. Drilon, Shunqi Yan, 2016, Clinical Cancer Research.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Joon-Oh Park, P. Stephens, J. Huh, 2015, Oncotarget.

Fidelity and Stability of PDX Models

G. Li, 2017 .

Patient-derived xenograft models for oncology drug discovery

G. Li, 2015 .

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

R. Bosotti, A. Isacchi, E. Felder, 2016, Molecular Cancer Therapeutics.

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia

E. Pomari, I. Silverman, Kristen M. Smith, 2017, Molecular Cancer Therapeutics.

Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs

R. Shoemaker, A. Bardelli, Kyoung-Mee Kim, 2015 .

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

M. Ciomei, A. Galvani, E. Ardini, 2014 .

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

A. Drilon, M. Ahn, S. Rangaraju, 2017 .